Extension of Time to File SOU

PTO- 1581

Approved for use through 12/31/2020. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1581

Approved for use through 12/31/2020. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: FYARRO (see, http://uspto.report/TM/88599810/mark.png)
SERIAL NUMBER: 88599810

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: AADi Bioscience, Inc., having an address of
      17383 Sunset Blvd., Suite A250
      Pacific Palisades, California 90272
      United States
      Email: XXXX
Proposed: AADi Bioscience, Inc., having an address of
      17383 Sunset Blvd., Suite A250
      Pacific Palisades, California 90272
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 09/22/2020.

For International Class 005:
Current identification: Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy, mitochondrial disease, central nervous system disease, infectious disease, and acute respiratory disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in in pediatric, geriatric, emergency, family, and psychiatry; pharmaceutical preparations for the treatment of infectious, hereditary, and physiological diseases

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


For International Class 042:
Current identification: Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

Correspondence Information (current):
      Aaron D. Hendelman
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@wsgr.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): trademarks@wsgr.com

Correspondence Information (proposed):
      Aaron D. Hendelman
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@wsgr.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $250 will be submitted with the form, representing payment for 2 classes.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Neil Desai/      Date Signed: 02/23/2021
Signatory's Name: Neil Desai
Signatory's Position: Founder, CEO & President
Signatory's Phone: Not Required
Signature method: Sent to third party for signature

PAYMENT: 88599810
PAYMENT DATE: 02/23/2021

Serial Number: 88599810
Internet Transmission Date: Tue Feb 23 15:06:14 ET 2021
TEAS Stamp: USPTO/ESU-XXX.X.XXX.XXX-2021022315061403
5057-88599810-77064e6998684f14e9c9038602
959f7d0c69af1a3677578cd5ff0b2dbdceeb65c-
DA-06123769-20210223135146316194